{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:38:28Z","timestamp":1787020708206,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>3-methylmethcathinone (3-MMC) has been available on the European drug market for several years, but an increase in its availability seems to have occurred around 2020, associated with reports of harm and death. We aimed to analyze the composition of the supposed 3-MMC samples purchased and its concordance with the assumed composition of the drug.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A prospective multicenter (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096) study was conducted between February 2021 and September 2021\u00a0in Auvergne-Rhone-Alpes, France. The inclusion criteria were: 3-MMC users over 18\u00a0years of age in contact with a community-based organization (CBO) called AIDES. Consumption was evaluated with an anonymized questionnaire and samples of 3-MMC powder were analyzed with a combination of qualitative (GC\u2013MS) and quantitative methods (UPLC-MS\/MS), to compare the assumed and real compositions of the products purchased.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We studied 45 samples provided by 33 users. The study population was predominantly male (91%), with a median age of 40\u00a0years, most were university graduates and regular users of 3-MMC. Intravenous drug use was reported by 15.2% of the population. Most of the users bought their 3-MMC online via the Clear Web. Drug testing was requested by 86% of the users, highlighting the need for this type of harm reduction strategy. The purity of the 3-MMC powder samples tested ranged from 21 to 98%. Other NPS drugs, such as 4-CEC (4-chloroethcathinone), 4-MMC, and 2-fluorodeschloroketamine (2-FDCK), supplied as methoxphenidine (MXP), were also detected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This prospective study shows that 3-MMC purity and dose vary considerably. It also describes the characteristics of 3-MMC users and their expectations of a drug-checking program. Our data suggest that drug-checking services may be useful in this population. Health associations and laboratories should work together to help increase access to such programs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-023-00836-4","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:01:41Z","timestamp":1690502501000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["NPAideS: a drug-checking study among 3-methylmethcathinone (3-MMC) users"],"prefix":"10.1186","volume":"20","author":[{"given":"Th\u00e9o","family":"Willeman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Grundig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Pochon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Michels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Charpentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Eysseric-Gu\u00e9rin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Fouilh\u00e9 Sam-Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Stanke-Labesque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Revol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,28]]},"reference":[{"key":"836_CR1","unstructured":"European monitoring centre for drugs and drug addiction. European drug report 2022: trends and developments 2022. https:\/\/www.emcdda.europa.eu\/publications\/edr\/trends-developments\/2022_en. Accessed 25 Oct 2022."},{"key":"836_CR2","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.drugpo.2018.02.002","volume":"55","author":"C Edmundson","year":"2018","unstructured":"Edmundson C, Heinsbroek E, Glass R, Hope V, Mohammed H, White M, et al. Sexualised drug use in the United Kingdom (UK): a review of the literature. Int J Drug Policy. 2018;55:131\u201348. https:\/\/doi.org\/10.1016\/j.drugpo.2018.02.002.","journal-title":"Int J Drug Policy"},{"key":"836_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.drugpo.2019.03.021","volume":"68","author":"J Sewell","year":"2019","unstructured":"Sewell J, Cambiano V, Speakman A, Lampe FC, Phillips A, Stuart D, et al. Changes in chemsex and sexual behaviour over time, among a cohort of MSM in London and Brighton: findings from the AURAH2 study. Int J Drug Policy. 2019;68:54\u201361. https:\/\/doi.org\/10.1016\/j.drugpo.2019.03.021.","journal-title":"Int J Drug Policy"},{"key":"836_CR4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/fcp.12725","volume":"36","author":"A Batisse","year":"2021","unstructured":"Batisse A, Eiden C, Deheul S, Monzon E, Djezzar S, Peyri\u00e8re H. Chemsex practice in France: an update in addictovigilance data. Fundam Clin Pharmacol. 2021;36:397\u2013404. https:\/\/doi.org\/10.1111\/fcp.12725.","journal-title":"Fundam Clin Pharmacol"},{"key":"836_CR5","doi-asserted-by":"publisher","first-page":"110743","DOI":"10.1016\/j.forsciint.2021.110743","volume":"321","author":"G Drevin","year":"2021","unstructured":"Drevin G, Rossi L-H, F\u00e9rec S, Briet M, Abbara C. Chemsex\/slamsex-related intoxications: a case report involving\u00a0gamma-hydroxybutyrate (GHB) and 3-methylmethcathinone (3-MMC) and a review of the literature. Forensic Sci Int. 2021;321:110743. https:\/\/doi.org\/10.1016\/j.forsciint.2021.110743.","journal-title":"Forensic Sci Int"},{"key":"836_CR6","unstructured":"World health organization. Critical review report\u202f: 3-methylmethcathinone (3-MMC), Expert Committee on drug dependence. 2016. https:\/\/cdn.who.int\/media\/docs\/default-source\/controlled-substances\/45th-ecdd\/3-mmc_draft.pdf?sfvrsn=f046b91f_1. Accessed 25 Oct 2022."},{"key":"836_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3109\/15563650.2014.981823","volume":"53","author":"M B\u00e4ckberg","year":"2015","unstructured":"B\u00e4ckberg M, Lindeman E, Beck O, Helander A. Characteristics of analytically confirmed 3-MMC-related intoxications from the Swedish STRIDA project. Clin Toxicol. 2015;53:46\u201353. https:\/\/doi.org\/10.3109\/15563650.2014.981823.","journal-title":"Clin Toxicol"},{"key":"836_CR8","doi-asserted-by":"publisher","unstructured":"Vincenti F, Gregori A, Flammini M, Di Rosa F, Salomone A. Seizures of New Psychoactive Substances on the Italian territory during the COVID-19 pandemic. Forensic Sci Int 2021;326:110904. https:\/\/doi.org\/10.1016\/j.forsciint.2021.110904.","DOI":"10.1016\/j.forsciint.2021.110904"},{"key":"836_CR9","doi-asserted-by":"publisher","first-page":"103293","DOI":"10.1016\/j.drugpo.2021.103293","volume":"95","author":"RPJ Koning","year":"2021","unstructured":"Koning RPJ, Benschop A, Wijffels C, Noijen J. Visitors of the Dutch drug checking services: profile and drug use experience. Int J Drug Policy. 2021;95:103293. https:\/\/doi.org\/10.1016\/j.drugpo.2021.103293.","journal-title":"Int J Drug Policy"},{"key":"836_CR10","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/dar.13370","volume":"41","author":"SA Borden","year":"2021","unstructured":"Borden SA, Saatchi A, Vandergrift GW, Palaty J, Lysyshyn M, Gill CG. A new quantitative drug checking technology for harm reduction: pilot study in Vancouver, Canada using paper spray mass spectrometry. Drug Alcohol Rev. 2021;41:410\u20138. https:\/\/doi.org\/10.1111\/dar.13370.","journal-title":"Drug Alcohol Rev"},{"key":"836_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12954-019-0351-1","volume":"17","author":"T Fleming","year":"2020","unstructured":"Fleming T, Barker A, Ivsins A, Vakharia S, McNeil R. Stimulant safe supply: a potential opportunity to respond to the overdose epidemic. Harm Reduct J. 2020;17:6. https:\/\/doi.org\/10.1186\/s12954-019-0351-1.","journal-title":"Harm Reduct J"},{"key":"836_CR12","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.toxac.2022.06.027","volume":"34","author":"M Augsburger","year":"2022","unstructured":"Augsburger M, D\u00e9glon J, Widmer C, Thomas A, Morger M\u00e9gevand R, Long\u00e8re S. Interest of drug checking supply: results of 3 years of activity in Geneva. Toxicol Anal Clin. 2022;34:S32\u20133. https:\/\/doi.org\/10.1016\/j.toxac.2022.06.027.","journal-title":"Toxicol Anal Clin"},{"key":"836_CR13","doi-asserted-by":"publisher","unstructured":"Marillier M, Batisse A, Richeval C, labrouve V. CHEMSEX, NPS & risk reduction management: preliminary results of a pilot study. Toxicol Anal Clin 2017; 29: 47\u201356. https:\/\/doi.org\/10.1016\/j.toxac.2016.12.003.","DOI":"10.1016\/j.toxac.2016.12.003."},{"key":"836_CR14","doi-asserted-by":"publisher","unstructured":"Strong C, Huang P, Li C-W, Ku SW-W, Wu H-J, Bourne A. HIV, Chemsex, and the need for harm-reduction interventions to support gay, bisexual, and other men who have sex with men. Lancet HIV 2022; https:\/\/doi.org\/10.1016\/S2352-3018(22)00124-2.","DOI":"10.1016\/S2352-3018(22)00124-2"},{"key":"836_CR15","unstructured":"Research C for DE and. Bioanalytical method validation guidance for industry. US food and drug administration 2020. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioanalytical-method-validation-guidance-industry. Accessed Nov 16 2021."},{"key":"836_CR16","doi-asserted-by":"publisher","first-page":"108875","DOI":"10.1016\/j.drugalcdep.2021.108875","volume":"226","author":"JL Flores Anato","year":"2021","unstructured":"Flores Anato JL, Panagiotoglou D, Greenwald ZR, Trottier C, Vaziri M, Thomas R, et al. Chemsex practices and pre-exposure prophylaxis (PrEP) trajectories among individuals consulting for PrEP at a large sexual health clinic in Montr\u00e9al, Canada (2013\u20132020). Drug Alcohol Depend. 2021;226:108875. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108875.","journal-title":"Drug Alcohol Depend"},{"key":"836_CR17","first-page":"1","volume":"14","author":"C G\u00e9rome","year":"2021","unstructured":"G\u00e9rome C. Usages et usagers de drogues en contexte de crise sanitaire. Tendances OFDT. 2021;14:1\u20138.","journal-title":"Tendances OFDT"},{"key":"836_CR18","unstructured":"European monitoring centre for drugs and drug addiction. EMCDDA initial report on the new psychoactive substance 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3- methylmethcathinone, 3-MMC). In accordance with Article 5b of Regulation (EC) No 1920\/2006 (as amended) 2021."},{"key":"836_CR19","first-page":"1","volume":"8","author":"S Cherki","year":"2022","unstructured":"Cherki S. Point SINTES. OFDT. 2022;8:1\u201315.","journal-title":"OFDT"},{"key":"836_CR20","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1080\/15563650.2022.2069575","volume":"60","author":"KM Scarfone","year":"2022","unstructured":"Scarfone KM, Maghsoudi N, McDonald K, Thompson H, Stefan C, Beriault DR, et al. Emerging synthetic cannabinoids detected by a drug checking service in Toronto. Canada Clin Toxicol. 2022;60:979\u201384. https:\/\/doi.org\/10.1080\/15563650.2022.2069575.","journal-title":"Canada Clin Toxicol"},{"key":"836_CR21","doi-asserted-by":"publisher","first-page":"110327","DOI":"10.1016\/j.forsciint.2020.110327","volume":"312","author":"MHY Tang","year":"2020","unstructured":"Tang MHY, Li TC, Lai CK, Chong YK, Ching CK, Mak TWL. Emergence of new psychoactive substance 2-fluorodeschloroketamine: Toxicology and urinary analysis in a cluster of patients exposed to ketamine and multiple analogues. Forensic Sci Int. 2020;312:110327. https:\/\/doi.org\/10.1016\/j.forsciint.2020.110327.","journal-title":"Forensic Sci Int"},{"key":"836_CR22","doi-asserted-by":"publisher","first-page":"110852","DOI":"10.1016\/j.forsciint.2021.110852","volume":"324","author":"T Gicquel","year":"2021","unstructured":"Gicquel T, Richeval C, Mesli V, Gish A, Hakim F, Pelletier R, et al. Fatal intoxication related to two new arylcyclohexylamine derivatives (2F-DCK and 3-MeO-PCE). Forensic Sci Int. 2021;324:110852. https:\/\/doi.org\/10.1016\/j.forsciint.2021.110852.","journal-title":"Forensic Sci Int"},{"key":"836_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12954-022-00617-5","volume":"19","author":"N Liebregts","year":"2022","unstructured":"Liebregts N, Rigoni R, Petru\u017eelka B, Bart\u00e1k M, Rowicka M, Zurhold H, et al. Different phases of ATS use call for different interventions: a large qualitative study in Europe. Harm Reduct J. 2022;19:36. https:\/\/doi.org\/10.1186\/s12954-022-00617-5.","journal-title":"Harm Reduct J"},{"key":"836_CR24","doi-asserted-by":"publisher","first-page":"103781","DOI":"10.1016\/j.drugpo.2022.103781","volume":"107","author":"I Rammohan","year":"2022","unstructured":"Rammohan I, Bouck Z, Fusigboye S, Bowles J, McDonald K, Maghsoudi N, et al. Drug checking use and interest among people who inject drugs in Toronto Canada. Int J Drug Policy. 2022;107:103781. https:\/\/doi.org\/10.1016\/j.drugpo.2022.103781.","journal-title":"Int J Drug Policy"},{"key":"836_CR25","doi-asserted-by":"publisher","first-page":"103037","DOI":"10.1016\/j.drugpo.2020.103037","volume":"88","author":"R Goncalves","year":"2021","unstructured":"Goncalves R, Titier K, Latour V, Peyr\u00e9 A, Castaing N, Daveluy A, et al. Suitability of infrared spectroscopy for drug checking in harm reduction centres. Int J Drug Policy. 2021;88:103037. https:\/\/doi.org\/10.1016\/j.drugpo.2020.103037.","journal-title":"Int J Drug Policy"},{"key":"836_CR26","doi-asserted-by":"publisher","first-page":"103741","DOI":"10.1016\/j.drugpo.2022.103741","volume":"106","author":"S Klaire","year":"2022","unstructured":"Klaire S, Janssen RM, Olson K, Bridgeman J, Korol EE, Chu T, et al. Take-home drug checking as a novel harm reduction strategy in British Columbia. Canada Int J Drug Policy. 2022;106:103741. https:\/\/doi.org\/10.1016\/j.drugpo.2022.103741.","journal-title":"Canada. Int J Drug Policy"},{"key":"836_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12954-017-0179-5","volume":"14","author":"L Harper","year":"2017","unstructured":"Harper L, Powell J, Pijl EM. An overview of forensic drug testing methods and their suitability for harm reduction point-of-care services. Harm Reduct J. 2017;14:52. https:\/\/doi.org\/10.1186\/s12954-017-0179-5.","journal-title":"Harm Reduct J"},{"key":"836_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.toxac.2021.11.006","volume":"34","author":"R Goncalves","year":"2022","unstructured":"Goncalves R, Pelletier R, Couette A, Gicquel T, Le Dar\u00e9 B. Suitability of high-resolution mass spectrometry in analytical toxicology: focus on drugs of abuse. Toxicol Anal Clin. 2022;34:29\u201341. https:\/\/doi.org\/10.1016\/j.toxac.2021.11.006.","journal-title":"Toxicol Anal Clin"},{"key":"836_CR29","unstructured":"European monitoring centre for drugs and drug addiction. Risk assessment report on the new psychoactive substance 1-(3-chlorophenyl)-2-(methylamino)propan-1-one (3-chloromethcathinone, 3-CMC) in accordance with Article 5c of Regulation (EC) No 1920\/2006 (As amended) 2022."},{"key":"836_CR30","unstructured":"European monitoring centre for drugs and drug addiction. European commission adopts measures to control two harmful new drugs amidst health concerns and surge in supply, News release No 3\/2022. 2022."}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-023-00836-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-023-00836-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-023-00836-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:01:49Z","timestamp":1690502509000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-023-00836-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,28]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["836"],"URL":"https:\/\/doi.org\/10.1186\/s12954-023-00836-4","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,28]]},"assertion":[{"value":"26 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from the HDH (Health Data Hub)\u00a0under number F20210126201110.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"96"}}